SyntheticGestalt, a company aiming to realise drug discovery by artificial intelligence, has today announced that it has entered into a joint research agreement with D. Western Therapeutics Institute, Inc. (hereinafter “DWTI”) with the aim of discovering new drug candidate compounds using SyntheticGestalt’s AI Drug Discovery System.
As the difficulty of discovering novel drug candidate compounds rises year on year, AI Drug Discovery is gaining traction as a potential enabler of breakthrough discoveries.
Combining DWTI’s knowledge base in the discovery of kinase inhibitors with SyntheticGestalt’s ability to select candidate compounds through machine learning-based drug discovery technology, the two parties will jointly strive to discover novel kinase inhibitors for the treatment of inflammatory and central nervous system (CNS) diseases.
Through this joint research project, SyntheticGestalt will aim to further demonstrate the value of its AI Drug Discovery system, in order to contribute as quickly as possible to the creation of novel therapy options for awaiting patients.